<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298439</url>
  </required_header>
  <id_info>
    <org_study_id>13-6128-AE</org_study_id>
    <nct_id>NCT02298439</nct_id>
  </id_info>
  <brief_title>Fatty Liver Patient Registry</brief_title>
  <official_title>Non-Alcoholic Fatty Liver Disease Patient Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Non-Alcoholic Fatty Liver Disease (NAFLD) registry is to collect
      demographic and clinical data on patients being treated for NAFLD and to determine the
      factors affecting the progression of the disease as well as the success of different
      treatment strategies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NAFLD registry is a local database provided by the principal investigator, Dr. J. Allard,
      which will be stored on the Research Intranet at the University Health Network, Toronto. The
      database will be password protected. Only clinic personnel and members of Dr. Allard's
      research team involved in the study will have access to the database. A code and date of
      birth will be used to identify each patient. All patients entering the NAFLD clinic at
      Toronto General Hospital will be consented for the registry. Only data from their regular
      clinic visits will be used for entry into the registry. Data entered into the registry will
      include: 1) Patient demography: age, sex, ethnicity, medical history; 2) Anthropometry:
      weight, height, BMI, waist circumference; 3) Nutritional assessment: Food records and food
      frequency questionnaires are kept by the subjects and data will be analyzed to assess the
      intake of macro- and micronutrients. Amount of alcohol and number of cigarette smoked will
      also be recorded; 4) Physical Activity will be assessed using the Paffenbarger Physical
      Activity Questionnaire; 5) Medications: insulin, non-steroidal anti-inflammatory drugs,
      corticosteroids, statins, medications used to treat diabetes/obesity (e.g. metformin,
      thiazolidinediones, orlistat…), medication to treat liver disease (eg. urso, carnitine,
      choline…), antioxidant vitamin or fish oil supplementation; 6) Blood work, currently
      including: complete blood count, biochemistry including liver enzymes, total protein,
      albumin, glucose, insulin, and blood lipid profile; other diagnostic blood work done to
      exclude other causes of liver disease, e.g. ceruloplasmin, anti-smooth muscle antibodies,…
      One plasma sample will be stored for assessment of cytokeratin 18 (CK-18) fragments as a
      novel marker for NASH in patients with NAFLD; 7) Presence of metabolic syndrome; 8) Disease
      categorization: SS, NASH, cirrhosis; 9) Survival: alive, death: causes, NAFLD-related or not
      NAFLD-related; 10) Liver biopsy results, NAFLD fibrosis score, and elastography results.

      Data will be entered after every clinic visit. Case report forms will be used to collect the
      data from the patient charts and facilitate data input into the registry database All
      patients will be followed prospectively until withdrawal from the clinic or death.
      Descriptive statistics will be performed. For the entire NAFLD population, probability of
      survival, cirrhosis, as well as liver and non-liver related morbidity will be calculated
      using the Kaplan Meier method.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Disease categorization</measure>
    <time_frame>Baseline</time_frame>
    <description>Specific diagnosis of NAFLD: simple steatosis (SS), steatohepatitis (NASH), cirrhosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease categorization</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Specific diagnosis of NAFLD: simple steatosis (SS), steatohepatitis (NASH), cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver biopsy results</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>NAFLD fibrosis score, and elastography results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Alive, death: causes, NAFLD-related or not</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient demography</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Age, sex, ethnicity, medical history from medical chart</description>
  </other_outcome>
  <other_outcome>
    <measure>Anthropometry</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Body mass index, waist circumference</description>
  </other_outcome>
  <other_outcome>
    <measure>Macro- and micronutrient intake</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Food records and food frequency questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>Physical activity</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Paffenbarger Physical Activity Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Presence of metabolic syndrome</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Medications</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>From clinical chart</description>
  </other_outcome>
  <other_outcome>
    <measure>Complete Blood Cell Count</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Routine laboratory test</description>
  </other_outcome>
  <other_outcome>
    <measure>Biochemistry</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Liver enzymes, total protein, albumin, glucose, insulin, and blood lipid</description>
  </other_outcome>
  <other_outcome>
    <measure>NAFLD specific diagnostic blood work</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>Ceruloplasmin, anti-smooth muscle antibodies</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytokeratin 18</measure>
    <time_frame>at each clinic visit, up to 5 years</time_frame>
    <description>CK-18 fragments</description>
  </other_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Non-Alcoholic Fatty Liver Disease (NAFLD )which includes simple steatosis
        (SS) and non-alcoholic steatohepatitis (NASH) that being treated
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients being treated for NAFLD at the Toronto General Hospital NAFLD clinic

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johane Allard, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>UHN</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anastasia Teterina, PhD</last_name>
    <phone>416-340-4104</phone>
    <email>anastasia.teterina@uhnresearch.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Akilen Rajadurai, PhD, BSc</last_name>
    <phone>416-340-4104</phone>
    <email>arajadur@uhnresearch.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johane P Allard, MD, FRCPC</last_name>
      <phone>416-340-5159</phone>
      <email>johane.allard@uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Anastasia Teterina, PhD</last_name>
      <phone>416-340-4104</phone>
      <email>anastasia.teterina@uhnresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Johane Allard, MD,FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014 Feb 21;20(7):1712-23. doi: 10.3748/wjg.v20.i7.1712. Review.</citation>
    <PMID>24587650</PMID>
  </results_reference>
  <results_reference>
    <citation>Monteiro J, Leslie M, Moghadasian MH, Arendt BM, Allard JP, Ma DW. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct. 2014 Mar;5(3):426-35. doi: 10.1039/c3fo60551e. Review.</citation>
    <PMID>24496399</PMID>
  </results_reference>
  <results_reference>
    <citation>Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008 Feb;48(2):300-7. Epub 2007 Nov 20.</citation>
    <PMID>18086506</PMID>
  </results_reference>
  <results_reference>
    <citation>Raman M, Allard J. Non alcoholic fatty liver disease: a clinical approach and review. Can J Gastroenterol. 2006 May;20(5):345-9. Review.</citation>
    <PMID>16691301</PMID>
  </results_reference>
  <results_reference>
    <citation>Allard JP. Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):783-95. Review.</citation>
    <PMID>12406445</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Johane Allard</investigator_full_name>
    <investigator_title>MD, FRCPC</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

